Literature DB >> 34515750

US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

Vincent Planche1,2, Nicolas Villain3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34515750     DOI： 10.1001/jamaneurol.2021.3126

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  6 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

2.  Mental health care for older adults: recent advances and new directions in clinical practice and research.

Authors:  Charles F Reynolds; Dilip V Jeste; Perminder S Sachdev; Dan G Blazer
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

3.  Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.

Authors:  Emily A Largent; Andrew Peterson; Jason Karlawish; Holly Fernandez Lynch
Journal:  Drugs Aging       Date:  2022-06-13       Impact factor: 4.271

4.  Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Authors:  Gregory S Day; Nikolaos Scarmeas; Richard Dubinsky; Katherine Coerver; Anitra Mostacero; Brooks West; Scott R Wessels; Melissa J Armstrong
Journal:  Neurology       Date:  2022-02-23       Impact factor: 11.800

5.  A call for better reporting of trials using surrogate primary endpoints.

Authors:  Anthony Muchai Manyara; Oriana Ciani; Rod S Taylor
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-26

6.  Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.

Authors:  Eleonora Lacorte; Antonio Ancidoni; Valerio Zaccaria; Giulia Remoli; Leonardo Tariciotti; Guido Bellomo; Francesco Sciancalepore; Massimo Corbo; Flavia L Lombardo; Ilaria Bacigalupo; Marco Canevelli; Paola Piscopo; Nicola Vanacore
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.